Literature DB >> 19485752

Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.

.   

Abstract

Vaccines have contributed enormously in reducing the impact of many infectious diseases, and the expanded use of new and existing vaccines provides unprecedented potential for further reducing the global burden of infectious diseases. Yet, as with the deployment of other technologies, their use may also sometimes be associated with undesirable effects that need to be identified rapidly, understood and minimized. In this article, we review the models and systems that have been developed to monitor and respond to concerns regarding vaccine safety and we give illustrative examples of real or perceived vaccine safety issues. The Global Advisory Committee on Vaccine Safety (GACVS) was set up 10 years ago and charged to provide the WHO with independent advice on vaccine safety issues. The role of the GACVS is both to analyze and to interpret reports of the adverse effects of vaccines that impact on global vaccination programs and strategies, and to foster the development of improved surveillance systems to detect any adverse effects of vaccines, particularly in low- and middle-income countries. It also monitors the development of new vaccines during clinical testing and advises on the safe use of vaccines in immunization programs. As success is achieved with reducing the burden of vaccine-preventable diseases, there will be increasing attention focused on potential adverse effects, on the development of effective surveillance systems to detect adverse effects, and on improved methods to manage and control any harmful consequences of vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19485752     DOI: 10.1586/erv.09.40

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  13 in total

1.  Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013.

Authors: 
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

2.  Overcoming barriers in HPV vaccination and screening programs.

Authors:  Alex Vorsters; Marc Arbyn; Marc Baay; Xavier Bosch; Silvia de Sanjosé; Sharon Hanley; Emilie Karafillakis; Pier Luigi Lopalco; Kevin G Pollock; Joanne Yarwood; Pierre Van Damme
Journal:  Papillomavirus Res       Date:  2017-07-20

Review 3.  Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.

Authors:  Edwin J Asturias; Melinda Wharton; Robert Pless; Noni E MacDonald; Robert T Chen; Nicholas Andrews; David Salisbury; Alexander N Dodoo; Kenneth Hartigan-Go; Patrick L F Zuber
Journal:  Vaccine       Date:  2016-05-16       Impact factor: 3.641

4.  Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.

Authors:  Punnee Pitisuttithum; Supachai Rerks-Ngarm; Valai Bussaratid; Jittima Dhitavat; Wirach Maekanantawat; Swangjai Pungpak; Pravan Suntharasamai; Sirivan Vanijanonta; Sorachai Nitayapan; Jaranit Kaewkungwal; Michael Benenson; Patricia Morgan; Robert J O'Connell; Jeffrey Berenberg; Sanjay Gurunathan; Donald P Francis; Robert Paris; Joseph Chiu; Donald Stablein; Nelson L Michael; Jean-Louis Excler; Merlin L Robb; Jerome H Kim
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

5.  Knowledge, practice and approaches of health professionals to adverse events following immunization and their reporting in Albania.

Authors:  Irsida Mehmeti; Erida Nelaj; Artan Simaku; Eugena Tomini; Silva Bino
Journal:  Heliyon       Date:  2017-06-20

Review 6.  Influenza vaccines: Evaluation of the safety profile.

Authors:  Claudia Maria Trombetta; Elena Gianchecchi; Emanuele Montomoli
Journal:  Hum Vaccin Immunother       Date:  2018-01-30       Impact factor: 3.452

7.  T-cell receptor excision circle levels and safety of paediatric immunization: A population-based self-controlled case series analysis.

Authors:  Kumanan Wilson; Daniel Rodriguez Duque; Malia S Q Murphy; Steven Hawken; Anne Pham-Huy; Jeffrey Kwong; Shelley L Deeks; Beth K Potter; Natasha S Crowcroft; Dennis E Bulman; Pranesh Chakraborty; Julian Little
Journal:  Hum Vaccin Immunother       Date:  2018-02-26       Impact factor: 3.452

Review 8.  COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials.

Authors:  Wenping Gong; Ashok Aspatwar; Shuyong Wang; Seppo Parkkila; Xueqiong Wu
Journal:  Expert Rev Vaccines       Date:  2021-06-15       Impact factor: 5.217

9.  Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.

Authors:  Fabien V K Diomandé; Téné M Yaméogo; Kirsten S Vannice; Marie-Pierre Preziosi; Simonetta Viviani; Claude-Roger Ouandaogo; Modibo Keita; Mamoudou H Djingarey; Nehemie Mbakuliyemo; Bartholomew Dicky Akanmori; Samba O Sow; Patrick L F Zuber
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

Review 10.  Aluminum Adjuvant-Containing Vaccines in the Context of the Hygiene Hypothesis: A Risk Factor for Eosinophilia and Allergy in a Genetically Susceptible Subpopulation?

Authors:  Todd D Terhune; Richard C Deth
Journal:  Int J Environ Res Public Health       Date:  2018-05-03       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.